SecBot SecBot
PRESS-RELEASE ·Filed Mar 5, 2026

CRBU

Caribou Biosciences, Inc.
MIXED
Impact 6/10
Horizonmonths Processed8mo ago WireGlobeNewswire
Press release · Earnings
Actionable Insight ◆ Mixed

While cost discipline improved non-GAAP losses and extended cash runway, the lack of revenue growth and continued net losses raise sustainability concerns. Upcoming 2026 clinical data readouts for vispa-cel and CB-011 will be critical catalysts. Investors should monitor whether Caribou secures additional funding ahead of the vispa-cel pivotal trial.

DirectionMixed
Confidencehigh
Horizonmonths

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$1.82
T+0 close · Mar 5, 2026 · via day close
Latest settled
+33.52%
T+60 · $2.43
Vs SPY
+20.74%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Mar 6 $1.82entry
  2. T+1 · 8mo ago +8.24%α +7.40% · $1.97
  3. T+5 · 8mo ago +3.30%α +4.83% · $1.88
  4. T+20 · 8mo ago +7.14%α +9.19% · $1.95
  5. T+60 · 6mo ago +33.52%α +20.74% · $2.43
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Caribou Biosciences reported fourth quarter and full-year 2025 financial results, highlighting clinical progress in its two allogeneic CAR-T programs, vispa-cel and CB-011, with upcoming data readouts expected in 2026. Revenue increased modestly, while R&D and G&A expenses declined due to workforce reductions and pipeline prioritization. The company reported a GAAP net loss of $148.1 million, including a $21.3 million non-cash impairment charge, and ended the year with $142.8 million in cash, sufficient to fund operations into 2H 2027.

Key Financial Metrics

Revenue
$11.2M
+11.7% YoY
Adj. EPS
$-1.36
GAAP: $-1.59

Key Facts

  • Licensing and collaboration revenue increased to $11.2 million in 2025 from $10.0 million in 2024.
  • R&D expenses decreased to $109.4 million in 2025 from $130.2 million in 2024 due to cost-cutting measures.
  • GAAP net loss was $148.1 million in 2025, slightly improved from $149.1 million in 2024.
  • Non-GAAP net loss improved to $126.8 million in 2025 from $149.1 million in 2024, excluding $21.3 million in non-cash impairment charges.
  • Cash, cash equivalents, and marketable securities declined to $142.8 million from $249.4 million at year-end 2024.
  • Company expects cash runway into 2H 2027 but is exploring options to fully fund the planned vispa-cel pivotal trial.
  • Longer follow-up data from ANTLER trial and initial dose expansion data for CB-011 expected in 2026.

Financial Impact

Revenue up 12% YoY to $11.2M; operating expenses down $17.1M; cash burn of $106.6M in 2025; $21.3M non-cash impairment charge.

revenuer_and_dg_and_anet_losscash

Risk Factors

  • High cash burn and declining cash reserves despite cost-cutting; may require dilutive financing.
  • Reliance on upcoming clinical data to validate 'best-in-class' claims without head-to-head trials.
  • Forward-looking statements carry significant risk given early-stage pipeline and regulatory uncertainty.

Market Snapshot

Exchange
Nasdaq

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3250668

Track record

13 reports on CRBU

Performance horizon

3 of 3 bullish or bearish reports moved the stock their way by T+20. Best: +28.02% at T+20 after the Oct 6, 2026 report. 4 of 4 went positive at some point.

Filters
  1. Nov 5, 202611d ago 8-K Bearish 7/10 Entry $0.4487 Now $0.3530 +21.33% settles Dec 7
  2. Oct 6, 20265w ago 8-K Bearish 7/10 Entry $0.6174 to $0.4444 Now $0.3530 +42.82% ▲ +28.02% +26.68% vs SPY
  3. Sep 22, 20267w ago Institutional Cluster Mixed 3/10 Entry $1.34 to $0.5190 Now $0.3530 −73.66% ▼ −61.27% −60.71% vs SPY
  4. Jun 11, 202622w ago 8-K Bullish 6/10 Entry $1.66 to $1.94 Now $0.3530 −78.73% ▲ +16.87% +14.98% vs SPY
  5. Jun 11, 202622w ago Press Release Bullish 7/10 Entry $1.66 to $1.94 Now $0.3530 −78.73% ▲ +16.87% +14.98% vs SPY
  6. Jun 5, 202623w ago DEFA14A Neutral 2/10 Entry $1.84 to $1.83 Now $0.3530 −80.82% ▼ −0.54% −2.17% vs SPY
  7. Apr 24, 202629w ago DEFA14A Neutral 3/10 Entry $2.13 to $2.16 Now $0.3530 −83.43% ▲ +1.41% −3.55% vs SPY
  8. Mar 5, 202636w ago 8-K Mixed 5/10 Entry $1.82 to $1.95 Now $0.3530 −80.60% ▲ +7.14% +9.19% vs SPY
  9. Mar 5, 202636w ago Press Release Mixed 6/10 Viewing Entry $1.82 to $1.95 Now $0.3530 −80.60% ▲ +7.14% +9.19% vs SPY
  10. Feb 28, 202637w ago Institutional Cluster Neutral 5/10 Entry $1.84 to $1.72 Now $0.3530 −80.82% ▼ −6.52% +1.42% vs SPY
Showing 10 of 13

US Market Status

Market Closed · Opens in 6h 29m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Mar 5, 2026